Skip to main content

Advertisement

Table 1 Summary results of three NCI-MATCH sub-studies [12,13,14]

From: Umbrella and basket trials in oncology: ethical challenges

Sub-study Pts enrolled N Pts evaluable for response N PR (%) SD (%) PD (%) PFS6 rate (%) Pts evaluable for toxicity N AEs (%) Grade 3/4 AEs (%) Comments
Arm W: Pts with FGFR1–3 mutation or translocation receive FGFR Inhibitor AZD4547 [12] 52 41 5 51 44 17 49 80 49 Failed to meet its primary endpoint
Arm Q: Pts with HER2 amplification receive trastuzumab emtansine [13] N/R 37 8.1 43 N/R 24.8 N/R N/R N/R Failed to meet its primary endpoint
Arm I: Pts with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib [14] 65 N/R 0 N/R N/R 27 N/R N/R N/R Failed to meet its primary endpoint; Co-occurring mutations were detected in 67% of tumors; 11% of pts. discontinued taselisib because of toxicity
  1. AEs Adverse events, N/R Not reported, OR Objective response, PD Progressive disease, PFS6 Progression-free survival at 6 months of treatment, PR Partial response, Pts Patients, SD Stable disease